ePrints

First-in-human phase 1 study of MLN2480, an investigational oral pan-RAF kinase inhibitor, in patients (pts) with relapsed or refractory solid tumors, including BRAF/NRAS-mutant melanoma

Lookup NU author(s): Professor Ruth Plummer

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Publication metadata

Author(s): Middleton M, Rasco DW, Olszanski AJ, Corrie P, Lorigan P, Plummer R, Larkin J, Pavlick A, Zhou X, Yuan Z, Gangolli E, Kneissl M, Bozon V, Gonzalez R

Publication type: Conference Proceedings (inc. Abstract)

Publication status: Published

Conference Name: 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Year of Conference: 2014

Pages: 117

Print publication date: 01/11/2014

Online publication date: 21/11/2014

ISSN: 1879-0852

Publisher: Elsevier

URL: http://dx.doi.org/10.1016/S0959-8049(14)70490-3

DOI: 10.1016/S0959-8049(14)70490-3

Series Title: European Journal of Cancer

Share